STOCK TITAN

PANBELA THERAPEUTICS INC - PBLA STOCK NEWS

Welcome to our dedicated page for PANBELA THERAPEUTICS news (Ticker: PBLA), a resource for investors and traders seeking the latest updates and insights on PANBELA THERAPEUTICS stock.

Panbela Therapeutics, Inc. (NASDAQ: PBLA) is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics to address unmet medical needs in cancer treatment and prevention. Headquartered in Minneapolis, Panbela's primary assets include Ivospemin (SBP-101) and Flynpovi.

Panbela's core business revolves around advancing its drug pipeline through clinical trials. The company has made significant strides in 2023 and early 2024, particularly with its Phase III ASPIRE trial, which targets untreated metastatic pancreatic ductal adenocarcinoma. This trial has surpassed 50% enrollment, bringing it closer to its goal of enrolling approximately 600 patients by Q1 2025. The recent approval of Onivyde in the same therapeutic area for the first time in over a decade augments Panbela's optimism regarding its interim analysis and potential for providing additional treatment options.

Financially, Panbela reported a net loss of $6.5 million in 2023's fourth quarter, with general and administrative expenses decreasing to $0.9 million. Research and development expenses rose to $6.1 million, reflecting the company's robust commitment to its clinical programs. As of December 31, 2023, Panbela had $2.6 million in cash and current assets totaling $3.1 million against current liabilities of $12.3 million. The completion of a public offering in January 2024 raised approximately $9 million in gross proceeds, bolstering the company's financial standing.

Panbela collaborates with renowned institutions like Johns Hopkins University School of Medicine, enhancing its research capabilities. The company's development programs encompass various cancers, including familial adenomatous polyposis (FAP), first-line metastatic pancreatic cancer, neoadjuvant pancreatic cancer, colorectal cancer prevention, ovarian cancer, and diabetes.

  • Ivospemin (SBP-101): This proprietary polyamine analogue aims to inhibit polyamine metabolism in pancreatic ductal adenocarcinoma and other tumors. Clinical studies have shown promising results, including a median overall survival of 14.6 months and an objective response rate of 48%, outperforming standard chemotherapy regimens. Ivospemin has not exacerbated chemotherapy-related adverse events, supporting its continued evaluation in the ASPIRE trial.
  • Flynpovi™: A combination of CPP-1X (eflornithine) and sulindac, Flynpovi inhibits polyamine synthesis and enhances polyamine catabolism. Phase III trials have demonstrated its efficacy in preventing precancerous sporadic adenomas and delaying surgical events in FAP patients. The safety profile of Flynpovi supports its ongoing evaluation.
  • CPP-1X (Eflornithine): Developed as a single agent for indications like gastric cancer prevention and recent onset Type 1 diabetes, CPP-1X has shown potential activity and tolerability in preclinical and early-phase trials.

Panbela's common stock is listed on the OTCQB market under the symbol “PBLA”. The company remains dedicated to advancing its clinical programs and maximizing stockholder value through strategic initiatives and potential regulatory approvals.

Rhea-AI Summary
Panbela Therapeutics announces acceptance of abstract on SBP-101 and CPP-1X research in multiple myeloma for online publication
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.82%
Tags
none
-
Rhea-AI Summary
Panbela Therapeutics, Inc. (Nasdaq: PBLA) will host a conference call on November 9, 2023, at 4:30 PM Eastern Time to discuss results for its third quarter ended September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.03%
Tags
conferences earnings
-
Rhea-AI Summary
Panbela Therapeutics announces Issue Notification for Chinese patent 201980010826.7 in collaboration with Syngene International Ltd. The patent claims a novel process to produce SBP-101 with reduced synthetic steps. Advantages include scalability, efficiency, and cost-effectiveness. This expands coverage into China and Asia, potentially reducing production costs and improving competitiveness.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.4%
Tags
none
Rhea-AI Summary
Panbela Therapeutics, Inc. to present at LD Micro Conference on October 4, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.29%
Tags
conferences
-
Rhea-AI Summary
Panbela Therapeutics announces the issuance of a Chilean patent for its lead investigational product, Flynpovi, developed in collaboration with Sanofi. The patent covers a fixed dose formulation of eflornithine and sulindac for the treatment of patients with Familial Adenomatous Polyposis (FAP). The patent is valid until 2036 and has been issued in multiple countries. This expands Panbela's patent portfolio and supports their global clinical programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.69%
Tags
none
-
Rhea-AI Summary
Panbela Therapeutics to present at H.C. Wainwright Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.76%
Tags
conferences
Rhea-AI Summary
Panbela Therapeutics announces European patent for novel process to produce SBP-101, reducing synthetic steps from 17 to 6. Patent valid until 2039. Expands patent portfolio and supports global clinical programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.23%
Tags
none
-
Rhea-AI Summary
Panbela Therapeutics, Inc. (Nasdaq: PBLA) provides a business update and reports financial results for Q2 2023. Key highlights include partnerships, clinical trial progress, financial/business updates, and communication of science. The company closed a registered public offering for $8.5 million and regained the North American rights to develop and commercialize Flynpovi tm. They also opened enrollment in the ASPIRE trial for pancreatic cancer and passed pre-planned futility analysis in the PACES Phase III trial for colorectal cancer. The company expects to deliver value creation by advancing its pipeline and executing against upcoming milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.14%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.48%
Tags
conferences earnings

FAQ

What is the current stock price of PANBELA THERAPEUTICS (PBLA)?

The current stock price of PANBELA THERAPEUTICS (PBLA) is $0.38 as of October 15, 2024.

What is the market cap of PANBELA THERAPEUTICS (PBLA)?

The market cap of PANBELA THERAPEUTICS (PBLA) is approximately 1.7M.

What is Panbela Therapeutics' primary focus?

Panbela Therapeutics is focused on developing innovative therapeutics for cancer treatment and prevention, addressing unmet medical needs.

What are Panbela's lead assets?

Panbela's lead assets include Ivospemin (SBP-101) and Flynpovi, both of which are in clinical trials targeting various types of cancer.

What is the status of the Phase III ASPIRE trial?

The Phase III ASPIRE trial for untreated metastatic pancreatic ductal adenocarcinoma has exceeded 50% enrollment, with full enrollment expected by Q1 2025.

What recent financial achievements has Panbela reported?

Panbela reported a net loss of $6.5 million for Q4 2023, with significant investments in research and development. The company raised approximately $9 million through a public offering in January 2024.

What collaborations does Panbela engage in?

Panbela collaborates with prestigious institutions like Johns Hopkins University School of Medicine to enhance its research and clinical trial capabilities.

What are the potential benefits of Ivospemin (SBP-101)?

Ivospemin has shown promising results in inhibiting tumor growth in pancreatic cancer, with a median overall survival of 14.6 months and an objective response rate of 48%.

What results have been observed with Flynpovi?

Flynpovi has demonstrated efficacy in preventing precancerous sporadic adenomas and delaying surgical events in FAP patients, with a supportive safety profile.

What is CPP-1X (Eflornithine) being developed for?

CPP-1X is being developed for several indications, including the prevention of gastric cancer and treating recent onset Type 1 diabetes.

Where is Panbela's stock listed?

Panbela's common stock is listed on the OTCQB market under the symbol 'PBLA'.

What is the significance of Panbela's recent public offering?

The recent public offering, which raised approximately $9 million, strengthens Panbela's financial position, enabling continued progress in its clinical programs.

PANBELA THERAPEUTICS INC

Nasdaq:PBLA

PBLA Rankings

PBLA Stock Data

1.70M
4.85M
0%
3.07%
Biotechnology
Healthcare
Link
United States of America
Waconia